Showing results (371-380 of 397) with videos related to
Sort By:
Pageof 40
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.Nature Immunology|October 4, 2016
Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitorsTiago C Luis, Sidinh Luc, Takuo Mizukami, et al.Cell Stem Cell|September 24, 2013
Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cellsCharlotta Böiers, Joana Carrelha, Michael Lutteropp, et al.Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.Blood|August 7, 2019
Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programsSorcha O'Byrne, Natalina Elliott, Siobhan Rice, et al.Science Translational Medicine|September 13, 2021
Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemiaDeena Iskander, Guanlin Wang, Elisabeth F Heuston, et al.Nature Immunology|May 30, 2024
Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cellsJoana Carrelha, Stefania Mazzi, Axel Winroth, et al.Science Translational Medicine|July 1, 2026
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisAlexandros Rampotas, Zoë C Wong, Isaac Gannon, et al.Blood Advances|November 24, 2020
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosisAaron T Gerds, Michael R Savona, Bart L Scott, et al.Blood|April 14, 2022
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapiesClara Bueno, Susana Barrera, Alex Bataller, et al.Pageof 40